

August 9, 2024

Listing Department Code: 532321

**BSE LIMITED** 

P J Towers, Dalal Street, Mumbai-400001

Listing Department Code: ZYDUSLIFE

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai-400051

Re: Change in Directors

Ref: <u>Disclosure under regulation 30 of SEBI (Listing Obligations and Disclosure</u>

Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Circular

dated July 13, 2023 ("the SEBI Circular")

Dear Sir,

Pursuant to the provisions of regulation 30 read with clause 7 of para A of part A of Schedule III of the Listing Regulations, we hereby inform that the shareholders of the Company at its Twenty Ninth Annual General Meeting ("AGM") held on August 9, 2024, passed necessary special resolutions for (i) re-appointment of Mr. Ganesh N. Nayak (DIN: 00017481) as the Whole Time Director (to be designated as the Executive Director) for one more year i.e. upto July 12, 2025, notwithstanding the fact that he shall attain the age of seventy years during the term of re-appointment and (ii) appointment of Ms. Shelina P. Parikh (DIN: 00468199) as an Independent Director for the first term of five consecutive years.

Further, Mr. Nitin R. Desai (DIN: 00140239) and Ms. Dharmishtaben N. Raval (DIN: 02792246) ceased as the Directors as well as the Independent Directors after the conclusion of the AGM, consequent upon completion of their respective tenures.





The requisite details as per the SEBI Circular are attached as **Annexure-"A"**.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED** 

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



## Annexure-"A"

Name of Director	Mr. Ganesh N. Nayak (DIN: 00017481)
Reason for change (re-appointment)	Re-appointment as the Whole Time Director, to be designated as Executive Director.
(i.e appointment)	as Executive 5 il editori
Date of re-appointment and term of re-appointment	The Board of Directors ("the <b>Board</b> ") at their meeting held on May 17, 2024, passed the resolution for re-appointment, subject to approval of shareholders, for one more year i.e. upto July 12, 2025, notwithstanding the fact that he shall attain the age of seventy years during the term of re-appointment.
	Shareholders at the Twenty Ninth Annual General Meeting held on August 9, 2024, passed the special resolution for reappointment.
	He is entitled to a fixed remuneration of Rs. 7.20 mio. per month and variable pay (commission) as may be recommended by the Nomination and Remuneration Committee ("NRC") and approved by the Board, subject to a maximum of Rs. 200.00 mio. for the Financial Year ending on March 31, 2025.
	For the period from April 1, 2025, to July 12, 2025, the remuneration will be as recommended by the NRC and approved by the Board.
Disclosure of relationship between Directors and Key Managerial Personnel inter-se	None
Brief profile	Mr. Ganesh N. Nayak, Executive Director, Zydus Lifesciences Limited spearheads business of the Zydus Group, including its Joint Ventures and Alliances. He joined the Zydus Cadila Group in 1977. With experience of more than 46 years, he has contributed significantly to the growth of the Company over the years. The Company has successfully undertaken several expansion plans during his association. With strategic insight



	and business acumen, Mr. Ganesh N. Nayak has played a key role in several M&A deals and alliances. Strategic management skills, long standing expertise in sales and marketing and new insights from the Harvard Business School have catapulted Mr. Ganesh N. Nayak to the global league of marketing professionals.
Declaration	In accordance with SEBI instructions to Stock Exchanges dated June 14, 2018, Mr. Ganesh N. Nayak has confirmed that he is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority.



Name of Director	Ms. Shelina P. Parikh (DIN: 00468199)
Reason for change (appointment)	Appointment as an Independent Director for the first term.
Date of appointment and term of appointment	The Board at their meeting held on May 17, 2024, passed the resolution for appointment, subject to approval of shareholders.  Shareholders at the Twenty Ninth Annual General Meeting held on August 9, 2024, passed the special resolution for appointment.  Term is appointment is for a period of 5 (five) consecutive years, not liable to retire by rotation.  She is entitled to receive sitting fees for attending the Board and committee meetings and commission as may be decided by the Board.
Disclosure of relationship between Directors and Key Managerial Personnel inter-se	None
Brief profile	Shelina Parikh is the Joint Managing Director of TechNova Group, a privately held, family business group with interests in imaging solutions, chemicals and industrial products.  Its main company, TechNova Imaging Systems, is the largest manufacturer of offset and digital print solutions in India, and the fifth largest in the world. TechNova's business portfolio covers Specialty Chemicals, Offset Printing Plates, Digital Print Media and Digital Print Equipment & Software. Globally recognised as a pioneer, TechNova's innovative products cater to a range of industries such as Commercial & Newspaper Printing, Packaging, Publishing, Signage, Photo, Textile and Medical Imaging.



As Joint MD, she is passionate about innovation, technology and mentoring leaders. She is instrumental in strengthening TechNova's strategic operations, business transformation, market leadership position, digitisation and new growth engines.
Her emphasis on the spiritual values of zero-ego, humility, trust, transparency, kindness and life-time employment are combined with a focus on high performance metrics, passion for excellence, leaner structures and strong corporate governance. This unique ethos has established a vibrant, innovative organisation that is recognised as a global leader in the Imaging Industry.
She is a member of Young Presidents Organisation and a founding member of Entrepreneurs Organisation in India.
She completed her B.A. from Brown University and MBA from Harvard Business School. She remains engaged with Harvard Business School, as Vice President of the HBS Global Alumni Board and member of the HBS South Asia Advisory Board.
In accordance with SEBI instructions to Stock Exchanges dated June 14, 2018, Ms. Shelina P. Parikh has confirmed that she is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such

**Declaration** 

authority.



Name of Director	Mr. Nitin R. Desai (DIN: 00140239)
Reason for change (cessation)	Ceased as the director as well as the Independent Director consequent upon completion of the tenure.
Date of cessation	After the conclusion of the 29 <sup>th</sup> Annual General Meeting held on August 9, 2024.
Disclosure of relationship between Directors and Key Managerial Personnel inter-se	Not Applicable
Brief profile	Not applicable



Name of Director	Ms. Dharmishtaben N. Raval (DIN: 02792246)
Reason for change (cessation)	Ceased as the director as well as the Independent Director consequent upon completion of the tenure.
Date of cessation	After the conclusion of the 29 <sup>th</sup> Annual General Meeting held on August 9, 2024.
Disclosure of relationship between Directors and Key Managerial Personnel inter-se	Not Applicable
Brief profile	Not applicable